Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anti CD3 and anti CD20 bispecific T cell engagers - Adagene

Drug Profile

Research programme: anti CD3 and anti CD20 bispecific T cell engagers - Adagene

Alternative Names: CD20xCD3 SAFE bsAb - Adagene; CD20xCD3 SAFE-bispecific antibodies - Adagene; CD20xCD3 SAFE-bsAbs - Adagene; CD20XCD3 T cell engagers - Adagene; CD3XCD20 bispecific T-cell engager programme - Adagene; SAFEbody CD20xCD3 BsAb T-cell Engager Programme - Adagene

Latest Information Update: 20 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Adagene
  • Class Antineoplastics; Bispecific antibodies; Immunoglobulin Fc fragments; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 20 Sep 2021 Anti CD3 and anti CD20 bispecific T cell engagers - Adagene is available for licensing as of 20 Sep 2021. https://www.adagene.com/contact/
  • 26 Aug 2021 Adagene announces intention to file IND application for Cancer in 2022
  • 29 Jul 2021 Adagene has patents pending for bispecific T cell engager targeting CD3 worldwide
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top